We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.25
Bid: 47.00
Ask: 47.50
Change: 0.50 (1.04%)
Spread: 0.50 (1.064%)
Open: 47.75
High: 48.50
Low: 46.25
Prev. Close: 48.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Fri, 01st May 2020 13:28

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Friday and not separately reported by Alliance News:

----------

Avacta Group PLC - biotherapeutics - Partnering with US-based Adeptrix to develop Covid-19 antigen test.

----------

Genedrive PLC - molecular diagnostics - Says development of SARS-CoV-2 testing kit passes manufacturing milestone. On track for CE marking in roughly three weeks.

----------

Inspiration Healthcare Group PLC - medical equipment - Says first consignment of ventilators arrived from supplier to the UK to be used by NHS.

----------

Frontier IP Group PLC - investor - Molendotech investee secures GBP425,000 in equity raise to fund development of rapid testing product for harmful bacteria. Says product receiving interest from potential customers attempting to tackle Covid-19.

----------

Catenae Innovation PLC - digital media - Builds data-protection compliant platform named Cov-ID to track user's Covid-19 test status. Expects project to enter trialling and finalisation phase in mid-May.

----------

Shield Therapeutics PLC - pharmaceuticals - Says manufacturing partners for Feraccru iron deficiency product continuing to work undisrupted. Too early to say whether sales in Germany and UK will hurt by Covid-19.

----------

Metals Exploration PLC - exploration and development - Operations in Philippines reduced to minimum to obey government measures. Says supply chain interruptions have meant some equipment deliveries delayed.

----------

Angus Energy PLC - oil and gas development - Says work to restart gas production at Saltfleetby continuing on schedule. In April sent tenders to bidders for various items for gas production at site. Says delaying bidding deadline due to Covid-19.

----------

Rose Petroleum PLC - oil and gas - Taken action to cost cuts amid virus and failed OPEC talks causing crude market turmoil. Directors taking 50% salary cut. Seeking shareholder approval for name change to Zephyr Energy PLC following restructuring last year.

----------

Rainbow Rare Earths Ltd - rare earth element miner - Says Gakara operations in Burundi continued mostly unhampered by Covid-19. Says 100 tonnes of concentrate reached Dar es Salaam, Tanzania by road due to air travel restrictions. Work continuing for maiden JORC resource.

----------

Igas Energy PLC - hydrocarbon producer - Shutting down some operations in May and June due to low oil price and market volatility. Closure to reduce production by about 600 barrels of oil equivalent per day. Will save roughly GBP500,000 in costs over the two months.

----------

Petra Diamonds Ltd - diamond miner - Says South African operations scaled up to 50% capacity as lockdowns ease. Says 3.8 million carats production guidance remains suspended. Chief executive and finance director take 25% salary cut.

----------

Ferro-Alloy Resources Ltd - vanadium mining - Says full-year results delayed amid UK Financial Conduct Authority moratorium. Production of acid-recoverable concentrates temporarily suspended due to Covid-19; other operations continue but at slower pace.

----------

Thor Mining PLC - tungsten explorer - Reducing costs and taking advantage of Covid-19 financial aid by Australian government.

----------

Lekoil Ltd - oil producer - Defers final USD7.6 million tranche of payment to Optimum Petroleum Development Co to cover costs at OPL 310 License. Payment now split into three tranches, starting with USD1.0 million in July before USD2.0 million in September.

----------

Danakali Ltd - potash producer - Says on-site activities in Eritrea suspended due to Covid-19. Expecting reduced costs in second quarter due to savings.

----------

Prairie Mining Ltd - coal developer - Poland operations limited as a result of pandemic travel restrictions.

----------

Bisichi PLC - miner - Says 2019 results delayed beyond April 30, after UK financial regulator allowed an extra two months.

----------

Salt Lake Potash Ltd - potash producer - Says virus has not had material impact on project schedules; operational changes in place to minimise Covid-19 impact. Directors and executives take 40% pay cut to save costs.

----------

Riverstone Credit Opportunities Income PLC - investor - Fair value of portfolio down 4.1% on March 31 from December 31 due to Covid-19 market turmoil and volatile commodity prices.

----------

Princess Private Equity Holding Ltd - investor - Says March 31 net asset value returns negative 14.1% in March alone and negative 14.8% in first quarter amid Covid-19 impact on markets.

----------

Arden Partners PLC - stockbroker - Says start to six months to April 30 was strong, despite UK political uncertainty amid Brexit and general election. Equity trading operation suffered "material losses" amid market response to virus. Says annual costs to be 25% lower year-on-year and board taking 40% salary cut. Some staff furloughed.

----------

James Cropper PLC - paper and advanced materials - Adjusted pretax profit for year ended March 28 to be in excess of GBP6 million, ahead of market expectations. Reports virus has reduced product demand across all divisions.

----------

Brickability Group PLC - construction materials - To begin re-opening of sites from Friday onwards.

----------

Quadrise Fuels International PLC - heavy fuel oil alternatives maker - Says GBP500,000 of cost savings achieved, meaning it can operate until second quarter of 2021 based on existing funds. Says operations continuing to "very good effect" despite Covid-19 restrictions.

----------

HML Holdings PLC - property services - Says profits for year ended March 31 slightly behind management expectations. Does not anticipate long-term impact from Covid-19, but sees reduction in ancillary revenue streams in the short-term.

----------

SpaceandPeople PLC - retail space selling and marketing - Reports GBP1 million funding application under UK's coronavirus business interruption loan scheme is successful.

----------

Bonhill Group PLC - media firm - Biggest impact from pandemic has been on events business. Says most events moved to second quarter. Furloughs 10% of UK workforce, reduces hours and implementes hiring freeze. Says cost cuts have led to savings of GBP2.5 million.

----------

Frontier Developments PLC - video game developer - Says lockdowns boosting demand and video game sales rising. Expects revenue for year to May 31 at top end of GBP65 million and GBP73 million range.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.